Active Implants LLC, a company that develops orthopedic implant solutions, announces that it has reached an exclusive agreement with Geistlich Pharma AG to be the exclusive Swiss distributor of the company’s NUsurface Meniscus Prothesis. The world’s first “artificial meniscus” is now available in Belgium, Germany, Israel, Italy, Switzerland and the UK.

The relationship between Active Implants and Geistlich Pharma began in 2019 with the launch of the MEFISTO project. The international effort under the EU Horizon2020 program is designed to develop interventions focused on joint preservation and delaying or preventing joint-sacrificing procedures such as knee replacement, thus reducing the social burden, associated costs and high levels of morbidity resulting from osteoarthritis (OA).

“With Geistlich Pharma’s focus on knee preservation through the regeneration of bone, cartilage and tissue, we feel confident that our two organizations are aligned in our core values. We look forward to expanding access to the NUsurface through their world-class medical education, training and support.”

Ted Davis, president and CEO of Active Implants

The NUsurface is reportedly the first artificial meniscus to be marketed in Europe and is currently under review by the US Food and Drug Administration (FDA), a media release from the company explains.

The medial meniscus replacement mimics the function of the natural meniscus and treats pain by redistributing loads transmitted across the knee joint. The NUsurface offers patients suffering from meniscus-deficient knee pain a safe and effective surgical alternative to knee replacement, an invasive procedure that is considered the current standard of care for patients unable to get relief from bracing/pain medications or arthroscopic surgery.

About the NUsurface Meniscus Prosthesis

The NUsurface Meniscus Prothesis is an artificial meniscus made from medical-grade polymer. As the result of its unique materials, composite structure and design, NUsurface does not require fixation to bone or soft tissues. NUsurface mimics the function of the natural meniscus by acting as a shock absorber to help distribute weight transmitted across the knee joint, reducing pain and improving physical function.

By limiting stress and protecting femoral articular cartilage from further damage, the NUsurface may be chondroprotective. It is currently marketed in Belgium, Germany, Israel, Italy, Switzerland and the UK.

Results from two US prospective, concurrent, clinical trials presented at the recent American Orthopedic Medicine Society-Arthroscopy Association of North America Combined 2021 Annual Meeting demonstrated that the NUsurface provided superior relief from post meniscus surgery knee pain when compared to treatment with non-surgical care alone, the release continues.

[Source(s): Active Implants LLC, Business Wire]

Related Content:
Meniscus Implant Relieves Pain in as Early as 6 Months
NUsurface Meniscus Implant Receives Breakthrough Device Designation
The NUsurface Artificial Meniscus is Now Available in Israel for the First Time